期刊文献+

miRNA-10b和Notch1在乳腺浸润性癌中的表达及临床意义

Expression and clinical significance of miRNA-10b and Notch1 in breast invasive ductal carcinoma
下载PDF
导出
摘要 目的探讨在乳腺浸润性癌组织中miRNA-10b和Notch1的表达及与临床病理特征之间的联系。方法收集2018年10月-2019年4月新疆医科大学第一附属医院的乳腺浸润性癌及癌旁正常组织的手术标本20例,采用RT-PCR和Westernblot检测miRNA-10b及Notch1的表达情况并分析两者的表达水平与乳腺浸润性癌临床参数之间的关系。结果RT-PCR结果显示,浸润性乳腺癌组织中miRNA-10b和Notch1的表达分别为癌旁乳腺组织的0.673倍(P=0.014)和3.564倍(P=0.033),miRNA-10b与Notch1呈负相关(r=-0.307),95%CI(0.668,0.171),差异无统计学意义;Westernblot结果显示Notch1在乳腺癌组织的蛋白表达量(0.990±0.059)高于癌旁正常组织的蛋白表达量(0.874±0.041),差异有统计学意义。miRNA-10b在原发病灶大、腋窝淋巴结有转移、TNM分期高及Ki-67数值大的患者中表达升高(P<0.05),而与年龄、组织学分级、ER、PR及HER-2的表达之间无相关性(P>0.05);Notch1与上述指标均无相关性(P>0.05)。结论miRNA-10b低表达可能会影响Notch1的高表达,并可能与侵袭、转移等不良预后相关。 Objective To investigatethe expression of miRNA-10b and Notch1 in breast invasive ductal carcinoma and its correlation with clinicopathological features.Methods Lesion and adjacent tissues of 20 invasive ductal carcinoma of breast cancer cases from the First Affiliated Hospital of Xinjiang Medical Universityfrom Oct.2018 to Apr.2019 were collected.RT-PCR and Western blotting were used to detect the expression of miRNA-10b and Notch1 and to analyze the relationship between their expression levels and the clinicopathological characteristics of invasive ductal carcinoma of the breast.Results RT-PCR results showed that the expression levels of miRNA-10b and Notch1 in the invasive breast cancer tissues were 0.673 times(P=0.014)and 3.564 times(P=0.033)as those in the adjacent breast tissues,respectively.MiRNA-10b was negatively correlated with Notch1(r=-0.307,95%CI0.668-0.171)with nostatistical difference.Western blotting results showed that the protein expression level of Notch1 in the breast cancer tissues(0.99±0.059)was higher than that in the adjacent normal tissues(0.874±0.041)with statistical difference.Combined with the analysis of clinical parameters of breast cancer,it was found that the expression of miRNA-10b was increased in the patients with large primary lesion,axillary lymph node metastasis,high TNM stage and large ki-67 value(P<0.05).However,there was no significant correlation with age,histological grade,ER,PR and HER-2(P>0.05).There was no significant correlation between Notch1 and the above indicators(P>0.05).Conclusion The low expression of miRNA-10b may affect the high expression of Notch1 and may be associated with poor prognosis such as invasion and metastasis.
作者 崔雅静 郭晨明 李慧芳 汪丹丹 地力木拉提·艾斯木吐拉 CUI Yajing;GUO Chenming;LI Huifang;WANG Dandan;Dilimulati Aisimutula(Department of The Breast Surgery,the First Affiliated Hospital of Xinjiang Medical University,Urumqi 830054,China)
出处 《新疆医科大学学报》 CAS 2020年第11期1437-1441,共5页 Journal of Xinjiang Medical University
基金 新疆维吾尔自治区自然科学基金面上项目(2017D01C302) 新疆医科大学研究生创新创业启动基金项目(CXCY2018019)。
关键词 乳腺癌 miRNA-10b NOTCH1 breast cancer miRNA-10b Notch1
  • 相关文献

参考文献4

二级参考文献32

  • 1Viale G,Regan MM,Maiorano E,et al.Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:BIG 1-98[J].J Clin Oncol,2007,25(25):3846-3852.
  • 2Rhodes A,Jasani B,Balaton AJ,et al.Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas:Correlation with patient age,assay sensitivity,threshold value,and mammographic screening[J].J Clin Pathol,2000,53(9):688-696.
  • 3Zhang Z,Wang J,Skinner KA,et al.Pathological features and clinical outcomes of breast cancer according to levels of oestrogen receptor expression[J].Histopathology,2014,65(4):508-516.
  • 4Harvey JM,Clark GM,Osbome CK,et al.Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J].J Clin Oncol,1999,17(5):1474-1481.
  • 5Elledge RM,Green S,Pugh R,et al.Estrogen receptor(ER)and progesterone receptor(PgR),by ligand-binding assay compared with ER,PgR and pS2,by immunohistocheniistiy in predicting response to tamoxifen in metastatic breast cancer:A Southwest Oncology Group study[J].Int J Cancer,2000,89?2):111-117.
  • 6Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].J Clin Oncol,2010,28(16):2784-2795.
  • 7Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25(1):118-145.
  • 8Goldhirsch A,Winer EP,Coates AS,et al.Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9);2206-2223.
  • 9Taylor CR,Levenson RM.Quantification of immunohistochemistry:Issues concerning methods,utility and semiquantitative assessment II[J].Histopathology,2006,49(4):411-424.
  • 10Yaziji H,Taylor CR,Goldstein NS,et al.Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry[J].Appl Immunohistochem Mol Morphol,2008,16(6):513-520.

共引文献557

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部